RIGL Rigel Corp: Price-to-Projected Revenue Ratio
Rigel Pharmaceuticals (RIGL) focuses on bringing drugs for autoimmune and hematological pathologies to market, expanding sales of Tavalisse. The forward P/S indicator clearly demonstrates the dynamics of this strategy, where the 10.80 level represents the current value. Growth is driven by premium pricing for original therapies, as well as a strong team of experts motivated by bonuses and a high-quality benefits package.
RIGL (Rigel Corp): analytical breakdowns and indicator data
- current price and projected stock value:
- company stock capitalization data:
- book value of equity indicators:
- debt and solvency information:
- financial results and valuation multiples details:
RIGL - Final Profit|Projected Future Earnings Rigel Pharmaceuticals|RIGL - P/E Multiple|Future Price to Earnings Rigel Pharmaceuticals Inc|RIGL - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rigel Corp|RIGL - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Rigel Pharmaceuticals|RIGL - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth rigel.com|RIGL - Net earnings per share growth this year|Earnings growth forecast for next year Rigel Pharmaceuticals
- sales volume and revenue indicators:
Summary company analytics:Rigel Pharmaceuticals, Inc. (RIGL)
Investors must find a balance between operational risks and the efficiency of capital returns. Stable demand for Rigel Pharmaceuticals (RIGL) hematology drugs generates a predictable cash flow. The forward P/S valuation history reflects the ratio of business value to expected annual revenue, revealing the capitalization's sensitivity to financial gaps. Current price action confirms the resilience of the model due to regular medication refills.
Key competitors
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|ABVX - Price-to-Projected Revenue Ratio|Forward Price to Sales ADMA (ADMA Corp)|PTGX: Forward P/S Multiple|IMVT - Market Cap to Expected Sales Ratio|KNSA (Kiniksa) - Forward P/S Multiple|GRFS - Projected Price to Revenue|Forward P/S Multiple ADPT|CLDX - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Aurinia Pharmaceuticals AUPH|biocryst.com - Price-to-Projected Revenue Ratio|VERA: Forward Price-to-Revenue Multiple|Forward Price to Sales DNTH (Dianthus Therapeutics Inc)|Pharvaris Corp (PHVS) - Price-to-Projected Revenue Ratio|Future Price to Revenue ABCL (AbCellera Corp)|TRML (Tourmaline Bio, Inc.) - Forward P/S Multiple|PGEN: Forward Price to Sales|Forward P/S Multiple PHAR|Forward P/S Multiple Nektar Therapeutics Inc (NKTR)|Price-to-Projected Revenue Ratio Upstream Bio Corp UPB|Forward Price to Sales ZBIO|IMNM - Price-to-Projected Revenue Ratio|gossamerbio.com (GOSS) - Forward Price-to-Revenue Multiple|KALV: Forward P/S Multiple|Septerna, Inc. (SEPN) - Forward P/S Multiple|PVLA (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Savara Pharma (SVRA)|Forward P/S Multiple ANAB|ATXS - Market Cap to Future Revenue Ratio|enGene - Forward Price-to-Revenue Multiple|Forward P/S Multiple RAPT Therapeutics Inc. RAPT|JBIO: Forward Price-to-Revenue Multiple|Aclaris Therapeutics, Inc - Price to Expected Revenue Ratio|KYTX: Forward P/S Multiple|TLSA - Market Cap to Expected Sales Ratio|CABA (Cabaletta Bio) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Ventyx Biosciences Inc. (VTYX)|Forward P/S Multiple THTX|Forward P/S Multiple Avalo Therapeutics Inc (AVTX)|Price-to-Projected Revenue Ratio Eledon Pharmaceuticals ELDN|agenusbio.com - Price-to-Projected Revenue Ratio|CLYM - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Zura Bio Ltd ZURA|aTyr (ATYR) - Price-to-Projected Revenue Ratio|Adagene Inc. - Forward Price to Sales|IMA (ImageneBio) - Forward P/S Multiple|Shattuck Therapeutics (STTK) - Market Cap to Expected Sales Ratio|Forward P/S Multiple EQ|connectbiopharm.com (CNTB) - Projected Price to Revenue|Price-to-Projected Revenue Ratio Immunic IMUX|Atara Biotherapeutics, Inc. - Price-to-Projected Revenue Ratio|IFRX - Price-to-Projected Revenue Ratio|Future Price to Revenue XFOR|ACET: Forward P/S Multiple|Celularity - Forward Price to Sales|INMB (INmune Bio Corp) - Forward P/S Multiple|Forward P/S Multiple Barinthus Biotherapeutics Corp|Price-to-Projected Revenue Ratio Kezar Life Sciences (KZR)|SABS (sabbiotherapeutics.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio Akari Therapeutics Plc AKTX|ENLV - Forward Price-to-Revenue Multiple|Q32 Bio Corp - Forward P/S Multiple|GOVX - Forward P/S Multiple|EDSA (Edesa Biotech, Inc.) - Forward Price-to-Revenue Multiple|ibioinc.com - Forward Price to Sales|CARM (Carisma Therapeutics Inc) - Forward P/S Multiple|XTL Biopharmaceuticals Ltd (XTLB) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Bolt Biotherapeutics (BOLT)|Forward Price-to-Revenue Multiple hcwbiologics.com HCWB|Price-to-Projected Revenue Ratio Aptevo Therapeutics Inc. APVO|AIM - Forward Price-to-Revenue Multiple|ADTX: Forward Price-to-Revenue Multiple|GRI - Forward P/S Multiple|XORTX (XRTX) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue HIND|REVB (Revelation Biosciences) - Forward P/S Multiple|Market Cap to Future Revenue Ratio indaptusrx.com INDP|Price-to-Projected Revenue Ratio Scinai Immunotherapeutics Ltd. (SCNI)|CALI (calcimedica.com) - Forward Price to Sales|Forward P/S Multiple AFMD (Affimed N.V.)|Market Cap to Expected Sales Ratio Allakos Inc (ALLK)|HOOKIPA - Forward P/S Multiple|Projected Price to Revenue IGM Biosciences, Inc. (IGMS)|ITOS: Forward P/S Multiple|Market Cap to Future Revenue Ratio Ocean Biomedical Inc (OCEA)|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Price-to-Projected Revenue Ratio THRD
